Quantcast

Global Ulcerative Colitis Market: Simponi and Entyvio Launches to Boost Growth by 2022

February 19, 2014

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ –

Reportstack has announced a newly published market intelligence report on Ulcerative
Colitis – Global Drug Forecast and Market Analysis to 2022
[http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ]
. The global ulcerative colitis (UC) market value
will increase steadily over the coming years, growing from almost $4.2 billion in 2012 to
approximately $6.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 4.7%. The
company’s latest report states that out of the 10 major countries (the US, Canada, France,
Germany, Italy, Spain, the UK, Japan, China and India), the US will continue to hold the
largest UC market share by 2020, with 52%. France and Germany will follow with shares of
11% and 8%, respectively.

Johnson & Johnson
[http://www.reportstack.com/product/140401/johnson-johnson-jnj-financial-and-strategic-swot-analysis-review.html ]
(J&J) has been continually dominating the UC market due to the
success of Remicade. However, Remicade’s patent is set to expire between 2015 and 2018,
which will knock J&J’s sales down from approximately $2 billion in 2012 to $1.5 billion by
2022, according to GlobalData. Another key player in the UC industry, AbbVie’s Humira,
will also lose its patent during the forecast period, with sales slipping from $1.2
billion in 2012 to $569 million by 2022.

However, the UC market will receive a major boost with the entry of J&J’s Simponi and
Takeda’s Entyvio, with sales expected to reach an estimated $576 million and $1.3 billion
by 2022, respectively. A senior Analyst covering Immunology, says: “Simponi shows better
efficacy in UC than Humira and will therefore allow J&J to retain its positive standing in
the UC industry for a longer period of time. On the other hand, Entyvio will have a slow
start before gradually reaching blockbuster status, as a result of its remarkably safe
profile for a biologic drug.”

Still, a number of barriers will limit any further growth in the UC market, including
the lack of curative therapy, diagnostic markers for disease severity, and biologic
treatment personalization.

The analyst concludes: “There is also a major need for preventive medicine that lowers
the associated risk of colorectal cancer, as well as demand for steroid replacement, oral
formulations and the management of infectious adverse events.”

During the coming decade, Europe is expecting the approval and launch of a UC
colectomy rescue therapy, InDex Pharmaceuticals’ Kappaproct. Kappaproct is targeting a
small patient population group, but due to the involvement of key gastroenterologists in
the development of this therapy, it will likely be welcomed for use in this new treatment
setting, which has never been addressed before by a pharmaceutical product. In addition,
Pfizer’s Xeljanz is expected to face low uptake post its estimated launch in 2017, owing
to the controversy surrounding its rejection by the EMA for its primary indication,
rheumatoid arthritis. The companies that are mentioned in this report are J&J, AbbVie,
Takeda, Warner Chilcott, Salix/Santarus, Shire, Ferring, Pfizer and InDeX Pharmaceuticals.

To view the detailed table of contents or to order this report kindly visit -
Ulcerative Colitis – Global Drug Forecast and Market Analysis to 2022
[http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ]

Related Reports from Reportstack:

MediPoint: Diagnostic Ultrasound Imaging – Global Analysis and Market Forecasts
[http://www.reportstack.com/product/149736/medipoint-diagnostic-ultrasound-imaging-global-analysis-and-market-forecasts.html ]

MediPoint: Bone Grafts and Substitutes – Global Analysis and Market Forecasts
[http://www.reportstack.com/product/149686/medipoint-bone-grafts-and-substitutes-global-analysis-and-market-forecasts.html ]

Biopsy Devices – Global Analysis and Market Forecasts
[http://www.reportstack.com/product/150581/biopsy-devices-global-analysis-and-market-forecasts.html ]

PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2022
[http://www.reportstack.com/product/150598/pharmapoint-schizophrenia-global-drug-forecast-and-market-analysis-to-2022.html ]

PharmaPoint: Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2022
[http://www.reportstack.com/product/146866/pharmapoint-dry-eye-syndrome-global-drug-forecast-and-market-analysis-to-2022.html ]

About Reportstack(TM):

Reportstack is one of the leading distributors of market research reports
[http://www.reportstack.com ] in the world today. Reportstack.com provides access to over
50,000 company profiles [http://www.reportstack.com ] and their strategic information like
SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new
product launches. Reportstack is also a leader in the field of Pharma market research
[http://www.reportstack.com/category/11/pharma-healthcare-market-research-reports.html ] &
Medical Devices Market Research Reports
[http://www.reportstack.com/subcategory_report/11/210/Pharma-Healthcare/medical-devices-market-research-reports.html ]
.

Contact Reportstack:

        Debora White
        Phone: +1 888-789-6604
        Email: debora@reportstack.com
        Followus: https://twitter.com/reportstack

SOURCE M/S. Reportstack


Source: PR Newswire



comments powered by Disqus